- ►annals.org [PDF] JT Schousboe, JA Nyman, RL Kane, KE … - Annals of internal medicine, 2005 - Am Coll Physicians Background: Treatment guidelines recommend drug treatment to prevent fractures
for some postmenopausal women who have low bone mass (osteopenia) but do not
have osteoporosis or a history of clinical fractures. Objective: To ... Cited by 65 - Related articles - All 7 versions
JT Schousboe, KE Ensrud, JA Nyman, RL … - Osteoporosis International, 2005 - Springer Abstract Prevalent vertebral deformities are predictive of future clinical
fractures independent of bone density. We used a Markov model with eight health
states to esti- mate from the societal perspective the cost-effectiveness ... Cited by 17 - Related articles - BL Direct - All 3 versions
SA Quandt, DE Thompson, DL Schneider, MC … - Mayo Clinic Proceedings, 2005 - mayoclinicproceedings.com Mayo Clin Proc. • March 2005;80(3):343-349 • www.mayoclinicproceedings.com ... From the Department of Public Health Sciences, Wake Forest University
School of Medicine, Winston-Salem, NC (SAQ); Merck Research Laborato- ries, ... Cited by 40 - Related articles - View as HTML - BL Direct - All 8 versions
JA Pasco, E Seeman, MJ Henry, EN Merriman … - Osteoporosis International, 2006 - Springer Abstract Introduction: Osteoporosis is associated with increased risk for
fracture. However, most postmenopausal women have bone mineral density (BMD)
within the normal or osteopenic range. The aim of this study was to ... Cited by 31 - Related articles - BL Direct - All 3 versions
ANA Tosteson, B Jönsson, DT Grima, BJ O' … - Osteoporosis International, 2001 - Springer Page 1. Original Article Challenges for Model-Based Economic Evaluations
of Postmenopausal Osteoporosis Interventions ANA Tosteson ... Cited by 54 - Related articles - BL Direct - All 3 versions
JA Kanis, F Borgstrom, O Johnell, B Jonsson - Osteoporosis International, 2004 - Springer Abstract Randomized, double-blind, controlled studies have shown that treatment
with risedronate reduces the risk of vertebral fracture in postmenopausal women
with established vertebral osteoporosis. They also show that the drug ... Cited by 48 - Related articles - BL Direct - All 4 versions
PM Christensen, K Brixen, D Gyrd-Hansen, IS … - Basic & Clinical Pharmacology & Toxicology, 2005 - interscience.wiley.com Abstract: Pharmacological interventions for osteoporosis may reduce morbidity
and mortality, but they incur additional health care costs. The aim was to
quantify the additional costs and health benefits of prescribing ... Cited by 17 - Related articles - All 4 versions
- ►adisonline.com [PDF] O Johnell, B Jonsson, L Jonsson, D Black - Pharmacoeconomics, 2003 - ingentaconnect.com 1 Department of Orthopedics, Malmö University Hospital, Malmö, Sweden 2 Center
for Health Economics, Stockholm School of Economics, Stockholm, Sweden 3
Department of Neuroscience, Occupational Therapy and Elderly Care Research ( ... Cited by 85 - Related articles - BL Direct - All 6 versions
JT Schousboe, KE Ensrud, JA Nyman, RL … - Journal of Clinical Densitometry, 2006 - Elsevier Most fractures occur in postmenopausal women who do not have osteoporosis by
bone density criteria (T-score > −2.5). Prevalent vertebral deformity is a
strong risk factor for incident fractures independent of bone mineral ... Cited by 14 - Related articles - BL Direct - All 6 versions
F Borgström, O Johnell, B Jönsson, N … - Bone, 2004 - Elsevier Background: One third of all the hip fractures occur in men. The risk for
mortality following hip fracture is higher for men compared to women. The
Fracture Intervention Trial (FIT) showed that the bisphosphonate ... Cited by 27 - Related articles - All 8 versions
